Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Cuts TP of HUTCHMED (00013.HK) to HKD30.4; Rating Outperform
Recommend 3 Positive 5 Negative 1 |
||||
|
||||
|
CLSA published a research report on HUTCHMED (00013.HK), which delivered mixed results for 2025, with sales figures falling short of forecast in light of commercial headwinds, while net profit exceeded expectations. The broker indicated that the 2026 oncology business guidance suggests an impending commercial recovery, and the new ATTC product line will be a key driver for results performance growth in the coming years. The target price was lowered from HKD31.4 to HKD30.4, maintaining the rating as Outperform. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
